MARKET

ZYNE

ZYNE

Zynerba Pharmace
NASDAQ
0.7821
-0.0783
-9.10%
After Hours: 0.8300 +0.0479 +6.12% 19:31 09/29 EDT
OPEN
0.8500
PREV CLOSE
0.8604
HIGH
0.8600
LOW
0.7701
VOLUME
466.00K
TURNOVER
0
52 WEEK HIGH
4.510
52 WEEK LOW
0.7701
MARKET CAP
35.78M
P/E (TTM)
-0.8395
1D
5D
1M
3M
1Y
5Y
Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
DEVON, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Stephen O’Quinn, P...
GlobeNewswire · 19h ago
Cannabis Stock Gainers And Losers From September 21, 2022
GAINERS: Icanic Brands (OTC:ICNAF) shares closed up 18.62% at $0.07
Benzinga · 09/21 20:35
Cannabis Stock Gainers And Losers From September 20, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 8.89% at $0.49
Benzinga · 09/20 21:28
Cannabis Stock Gainers And Losers From September 15, 2022
GAINERS: iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 5.70% at $0.06 LOSERS:
Benzinga · 09/15 20:36
Cannabis Stock Gainers And Losers From September 12, 2022
GAINERS: Icanic Brands (OTC:ICNAF) shares closed up 9.79% at $0.08
Benzinga · 09/12 20:32
Zynerba Pharmaceuticals Presents Data From Phase 2 INSPIRE Trial In 22q At The Society For Study Of Behavioural Phenotypes (SSBP) 24th International Research Symposium
 Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society
Benzinga · 09/08 13:16
Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Cha...
GlobeNewswire · 09/06 11:00
Bearish Sentiment Across The Cannabis Space - Check Full Movers For September 2, 2022
GAINERS: Cipher Pharmaceuticals (OTC:CPHRF) shares closed up 6.60% at $2.10
Benzinga · 09/02 21:16
More
About ZYNE
Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The Company is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. It has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.